Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in *Diabetes Care*.

Noting that Wnt/β-catenin signaling is related to the pathology of various diseases, Sonia Morales-Santana, Ph.D., from the Hospital Universitario San Cecilio in Granada, Spain, and colleagues measured serum sclerostin levels in 78 patients with type 2 diabetes mellitus, of whom 44 had atherosclerotic disease.

The researchers found that patients with atherosclerotic disease had...
significantly higher serum sclerostin levels, with a 4 percent increase in the risk of atherosclerotic disease for each 1 pmol/L increase in sclerostin. A sclerostin cut-off of 42.3 pmol/L could detect an increased risk of atherosclerotic disease with a sensitivity of 69 percent and a specificity of 54.8 percent. Higher sclerostin levels were associated with abnormal intima-media thickness and aortic calcification in both men and women, and with carotid plaques in men only. Homocysteine levels and intima-media thickness were positively correlated with sclerostin.

"Circulating sclerostin is increased in type 2 diabetes mellitus patients with atherosclerotic lesions," Morales-Santana and colleagues conclude.

More information: Abstract Full Text (subscription or payment may be required)

Health News Copyright © 2013 HealthDay. All rights reserved.


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.